Commitments and Contingencies - Summary of Potential Milestone Payments (Detail) - Sphaera Agreement [Member] |
Dec. 31, 2020
USD ($)
|
---|---|
Commitments and Contingencies Disclosure [Line Items] | |
Total potential milestone payments | $ 5,625,000 |
First Dosing of Patient in US Phase 1 Trial | |
Commitments and Contingencies Disclosure [Line Items] | |
Total potential milestone payments | 250,000 |
US Phase 1 Trial Completion With Endpoints Met | |
Commitments and Contingencies Disclosure [Line Items] | |
Total potential milestone payments | 500,000 |
US Phase 2 Trial Completion With Endpoints Met | |
Commitments and Contingencies Disclosure [Line Items] | |
Total potential milestone payments | 875,000 |
FDA Approval | |
Commitments and Contingencies Disclosure [Line Items] | |
Total potential milestone payments | $ 4,000,000 |
X | ||||||||||
- Definition Commitments and Contingencies Disclosure [Line Items] No definition available.
|
X | ||||||||||
- Definition Potential Milestone Payment Amount No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|